vs
Ultragenyx Pharmaceutical Inc.（RARE）与Revolve Group, Inc.（RVLV）财务数据对比。点击上方公司名可切换其他公司
Revolve Group, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.6倍（$324.4M vs $207.3M），Revolve Group, Inc.净利率更高（5.7% vs -62.0%，领先67.7%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 10.4%），Revolve Group, Inc.自由现金流更多（$-13.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 9.5%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
Revolve Theatre Company是总部位于英国泰晤士河畔亨利的剧团，专注于创作演出政治题材和莎士比亚系列戏剧作品，由奥利弗·登奇、乔·莫里斯与汤姆·史密斯共同创立运营。
RARE vs RVLV — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $207.3M | $324.4M |
| 净利润 | $-128.6M | $18.6M |
| 毛利率 | — | 53.3% |
| 营业利润率 | -54.7% | 6.3% |
| 净利率 | -62.0% | 5.7% |
| 营收同比 | 25.9% | 10.4% |
| 净利润同比 | 3.5% | 50.4% |
| 每股收益（稀释后） | $-1.28 | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $207.3M | $324.4M | ||
| Q3 25 | $159.9M | $295.6M | ||
| Q2 25 | $166.5M | $309.0M | ||
| Q1 25 | $139.3M | $296.7M | ||
| Q4 24 | $164.6M | $293.7M | ||
| Q3 24 | $139.5M | $283.1M | ||
| Q2 24 | $147.0M | $282.5M | ||
| Q1 24 | $108.8M | $270.6M |
| Q4 25 | $-128.6M | $18.6M | ||
| Q3 25 | $-180.4M | $21.2M | ||
| Q2 25 | $-115.0M | $10.2M | ||
| Q1 25 | $-151.1M | $11.8M | ||
| Q4 24 | $-133.2M | $12.3M | ||
| Q3 24 | $-133.5M | $11.0M | ||
| Q2 24 | $-131.6M | $15.4M | ||
| Q1 24 | $-170.7M | $10.9M |
| Q4 25 | — | 53.3% | ||
| Q3 25 | — | 54.6% | ||
| Q2 25 | — | 54.1% | ||
| Q1 25 | — | 52.0% | ||
| Q4 24 | — | 52.5% | ||
| Q3 24 | — | 51.2% | ||
| Q2 24 | — | 54.0% | ||
| Q1 24 | — | 52.3% |
| Q4 25 | -54.7% | 6.3% | ||
| Q3 25 | -106.9% | 7.1% | ||
| Q2 25 | -64.8% | 5.8% | ||
| Q1 25 | -102.6% | 5.0% | ||
| Q4 24 | -74.3% | 3.9% | ||
| Q3 24 | -94.6% | 5.0% | ||
| Q2 24 | -79.1% | 5.8% | ||
| Q1 24 | -151.9% | 3.4% |
| Q4 25 | -62.0% | 5.7% | ||
| Q3 25 | -112.8% | 7.2% | ||
| Q2 25 | -69.0% | 3.3% | ||
| Q1 25 | -108.5% | 4.0% | ||
| Q4 24 | -80.9% | 4.2% | ||
| Q3 24 | -95.7% | 3.9% | ||
| Q2 24 | -89.5% | 5.4% | ||
| Q1 24 | -156.8% | 4.0% |
| Q4 25 | $-1.28 | $0.27 | ||
| Q3 25 | $-1.81 | $0.29 | ||
| Q2 25 | $-1.17 | $0.14 | ||
| Q1 25 | $-1.57 | $0.16 | ||
| Q4 24 | $-1.34 | $0.18 | ||
| Q3 24 | $-1.40 | $0.15 | ||
| Q2 24 | $-1.52 | $0.21 | ||
| Q1 24 | $-2.03 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $421.0M | $292.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-80.0M | $512.5M |
| 总资产 | $1.5B | $765.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $421.0M | $292.3M | ||
| Q3 25 | $202.5M | $315.4M | ||
| Q2 25 | $176.3M | $310.7M | ||
| Q1 25 | $127.1M | $300.8M | ||
| Q4 24 | $174.0M | $256.6M | ||
| Q3 24 | $150.6M | $252.8M | ||
| Q2 24 | $480.7M | $244.7M | ||
| Q1 24 | $112.3M | $273.4M |
| Q4 25 | $-80.0M | $512.5M | ||
| Q3 25 | $9.2M | $490.2M | ||
| Q2 25 | $151.3M | $468.6M | ||
| Q1 25 | $144.2M | $453.4M | ||
| Q4 24 | $255.0M | $437.8M | ||
| Q3 24 | $346.8M | $420.8M | ||
| Q2 24 | $432.4M | $405.8M | ||
| Q1 24 | $140.3M | $389.9M |
| Q4 25 | $1.5B | $765.0M | ||
| Q3 25 | $1.2B | $751.3M | ||
| Q2 25 | $1.3B | $722.9M | ||
| Q1 25 | $1.3B | $713.9M | ||
| Q4 24 | $1.5B | $665.5M | ||
| Q3 24 | $1.5B | $670.9M | ||
| Q2 24 | $1.6B | $657.8M | ||
| Q1 24 | $1.3B | $650.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-99.8M | $-10.2M |
| 自由现金流经营现金流 - 资本支出 | $-100.8M | $-13.3M |
| 自由现金流率自由现金流/营收 | -48.6% | -4.1% |
| 资本支出强度资本支出/营收 | 0.5% | 1.0% |
| 现金转化率经营现金流/净利润 | — | -0.55× |
| 过去12个月自由现金流最近4个季度 | $-472.0M | $48.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-99.8M | $-10.2M | ||
| Q3 25 | $-91.4M | $11.8M | ||
| Q2 25 | $-108.3M | $12.6M | ||
| Q1 25 | $-166.5M | $45.1M | ||
| Q4 24 | $-79.3M | $3.9M | ||
| Q3 24 | $-67.0M | $9.1M | ||
| Q2 24 | $-77.0M | $-24.7M | ||
| Q1 24 | $-190.7M | $38.4M |
| Q4 25 | $-100.8M | $-13.3M | ||
| Q3 25 | $-92.7M | $7.5M | ||
| Q2 25 | $-110.7M | $10.4M | ||
| Q1 25 | $-167.8M | $43.4M | ||
| Q4 24 | $-79.5M | $2.1M | ||
| Q3 24 | $-68.6M | $8.0M | ||
| Q2 24 | $-79.0M | $-25.7M | ||
| Q1 24 | $-193.9M | $36.7M |
| Q4 25 | -48.6% | -4.1% | ||
| Q3 25 | -58.0% | 2.5% | ||
| Q2 25 | -66.5% | 3.4% | ||
| Q1 25 | -120.5% | 14.6% | ||
| Q4 24 | -48.3% | 0.7% | ||
| Q3 24 | -49.2% | 2.8% | ||
| Q2 24 | -53.7% | -9.1% | ||
| Q1 24 | -178.2% | 13.5% |
| Q4 25 | 0.5% | 1.0% | ||
| Q3 25 | 0.8% | 1.5% | ||
| Q2 25 | 1.5% | 0.7% | ||
| Q1 25 | 1.0% | 0.6% | ||
| Q4 24 | 0.1% | 0.6% | ||
| Q3 24 | 1.2% | 0.4% | ||
| Q2 24 | 1.4% | 0.4% | ||
| Q1 24 | 3.0% | 0.6% |
| Q4 25 | — | -0.55× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | -1.60× | ||
| Q1 24 | — | 3.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
